Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Questcor regains some ground after Acthar hit but coverage concerns linger

This article was originally published in Scrip

Executive Summary

On 20 September, Questcor Pharmaceuticals' stock recovered some of the value lost the previous day when the per-share price was cut almost in half after reports that US health insurance company Aetna would cover only one of the 19 approved indications for HP Acthar gel (repository corticotropin injection) (scripintelligence.com, 20 September 2012).

You may also be interested in...



Mallinckrodt's FTC Settlement Seems A Blip For Acthar Blockbuster

Company anticipates steady sales of its blockbuster treatment for infantile spasms and other severe conditions for many years, despite agreement to out-license a potential competitor as part of settlement with US trade commission. Settlement resolving investigation into earlier Questcor acquisition also includes $100m fine.

Slow And Steady: Merck Advances COVID-19 Antiviral, Vaccine Programs

Merck’s third quarter beat analyst consensus and the company raised its guidance. The COVID-19-battered vaccines business began to improve but Gardasil’s recovery was slower than expected.

Amgen Faces Potential Lack Of Near-Commercial Assets

Amgen’s R&D programs are vitally important as sales of multiple blockbusters continue to drop, but one major late-stage asset had disappointing results and another key drug has an aggressive competitor.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1134409

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel